| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000033917 |
| Receipt No. | R000038682 |
| Scientific Title | A Study for the effect of Bifidobacterium-containing food intake on cognitive function for healthy elderly subject |
| Date of disclosure of the study information | 2018/08/28 |
| Last modified on | 2019/11/04 (Ver. 8) |
| Basic information | ||
| Public title | A Study for the effect of Bifidobacterium-containing food intake on cognitive function for healthy elderly subject | |
| Acronym | A Study for the effect of Bifidobacterium-containing food intake on cognitive function | |
| Scientific Title | A Study for the effect of Bifidobacterium-containing food intake on cognitive function for healthy elderly subject | |
| Scientific Title:Acronym | A Study for the effect of Bifidobacterium-containing food intake on cognitive function | |
| Region |
|
|
| Condition | ||
| Condition | None (Healthy adult) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the effect on cognitive function of Bifidobacterium-containing food intake for 12 consecutive weeks |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Cognitrax (memory) at 12 week ingestion |
| Key secondary outcomes | Cognitrax (others) and BDNF at 12 week ingestion |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of Bifidobacterium-containing food for 12 consecutive weeks | |
| Interventions/Control_2 | Ingestion of placebo for 12 consecutive weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Healthy male and female aged from 50 to 69
2)Subjects with self-awareness of forgetfulness 3)Subjects with inferior scores of cognitive function tests |
|||
| Key exclusion criteria | 1)Subjects who are difficult to discriminate color
2)Subjects with bad eyesight, or are diagnosed with amblyopia or blindness 3)Subjects with bad hearing, or are diagnosed with hearing loss or permanent hearing loss 4)Subjects with history of cranial nerve disease 5)Subjects who are under treatment of cognitive functions, or are prescribed with medicine for them 6)Subjects who are suspected dementia 7)Subjects who have depressive symptoms, or who have been diagnosed as depressive disorder 8)Subjects who are under hormone treatment or who have been diagnosed as menopausal symptoms 9) Subjects who have a pain or disease that troubles with keystrokes 10)Subjects who have some irregular schedules during the study, due to night work or something 11)Subjects who drink much alcohol 12)Subjects who smoke, or quit smoking within one year before pre-inspection 13)Subjects who have done the same cognitive function test within one yea4 14)Subjects who continuously take medicine, health foods related to cognitive functions and/or rich in lactic acid bacteria 15)Subjects who was given or donated 200 ml or 400 ml whole blood within three months before pre-inspection 16)Subjects who participated in other study within one month before pre-inspection, or are going to participate in other study during the study 17)Subjects who have a disease which needs regular medication, or have a history of the disease 18)Subjects who are judged as unsuitable for the study by investigator because of clinical test, anthropometric test and physical examination in pre-inspection 19)Subjects who have possibilities for emerging allergy onset related to the study 20)Subjects who are pregnant or lactating, or plan to become pregnant or lactate during the study 21)Subjects who are judged as unsuitable for the study because of lifestyle questionnaire 22)Subjects who are judged as unsuitable for the study by investigator for other reasons |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | NISSIN FOODS HOLDINGS CO., LTD.
R&D Platform NISSIN Global Innovation Center |
||||||
| Division name | Health Science Research Office | ||||||
| Zip code | 192-0001 | ||||||
| Address | 2100, Tobukimachi, Hachioji, Tokyo | ||||||
| TEL | 042-696-7685 | ||||||
| Soichi.tanabe@nissin.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TTC Co., Ltd. | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 150-0021 | ||||||
| Address | Seibu Shinkin Bank Ebisu Bldg., 1-20-2, Ebisunishi, Shibuya-ku, Tokyo | ||||||
| TEL | 03-5459-5329 | ||||||
| Homepage URL | |||||||
| t.nakagawa@ttc-tokyo.co.jp | |||||||
| Sponsor | |
| Institute | TTC Co., Ltd |
| Institute | |
| Department | |
| Funding Source | |
| Organization | NISSIN FOODS HOLDINGS CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Aisei Hospital Ueno Clinic Research Ethics Committee |
| Address | 2-18-6, Higashiueno, Taitou-ku, Tokyo |
| Tel | 03-6455-0880 |
| t.saito@ttc-smo.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 60 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038682 |